Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia

Key facts

Sponsor

ECOG-ACRIN Cancer Research Group

Principal Investigator

Anand Jillella, MD

ECOG-ACRIN Cancer Research Group

Intervention

Simplified Patient Care Strategy(other)

Enrollment

202 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2027

Study locations (30)

• Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
• Kaiser Permanente-Anaheim, Anaheim, California, United States
• Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
• Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
• Kaiser Permanente-Bellflower, Bellflower, California, United States
• Kaiser Permanente-Fontana, Fontana, California, United States
• Kaiser Permanente-Fremont, Fremont, California, United States
• Fresno Cancer Center, Fresno, California, United States
• Kaiser Permanente-Fresno, Fresno, California, United States
• Kaiser Permanente - Harbor City, Harbor City, California, United States
• Kaiser Permanente-Irvine, Irvine, California, United States
• Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
• Kaiser Permanente-Cadillac, Los Angeles, California, United States
• Kaiser Permanente-Modesto, Modesto, California, United States
• Kaiser Permanente Oakland-Broadway, Oakland, California, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute promyelocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07563179
  Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
  Shenzhen University General Hospital
• RECRUITINGPHASE3NCT07504458
  Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
  Quetzal Therapeutics
• RECRUITINGPHASE3NCT07223814
  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
  Stichting Hemato-Oncologie voor Volwassenen Nederland
• ACTIVE NOT RECRUITINGNANCT07187505
  Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
  Anhui Medical University
• RECRUITINGPHASE3NCT07503730
  Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).
  First Affiliated Hospital Xi'an Jiaotong University
• ENROLLING BY INVITATIONNANCT06697327
  Daunorubicin + Cytarabine + Venetoclax in de Novo AML
  Anhui Medical University
• RECRUITINGPHASE1NCT06313437
  Revumenib in Combination With 7+3 + Midostaurin in AML
  Richard Stone, MD
• RECRUITINGPHASE3NCT06578247
  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
  Daiichi Sankyo

See all trials for Acute promyelocytic leukemia →